Monday, 25 March 2019
Latest news
Main » Nektar Therapeutics (NKTR) Received Consensus Recommendation of "Purchase" by Analysts

Nektar Therapeutics (NKTR) Received Consensus Recommendation of "Purchase" by Analysts

16 April 2018

The investor checklist may include studying the scope of a company's competitive industry advantage, examining company management, and trying to get a general feel if the stock is valued properly. At the end of 2017Q4, the 1.03M shares of the major pharmaceuticals company held by the institutional investor were priced at $61.47 million, down from 1.24 million at the end of the previous reported quarter. First Light Asset Management Llc who had been investing in Nektar Therapeutics for a number of months, seems to be less bullish one the $16.59 billion market cap company.

The stock decreased 2.35% or $0.45 during the last trading session, reaching $18.72.

Seagate Technology plc (STX) remained successful in beating the consensus-estimated $1.35 as it actually earned $1.48 per share in its last reported financial results. Nektar Therapeutics (NASDAQ:NKTR) has risen 347.01% since April 13, 2017 and is uptrending. It has outperformed by 335.46% the S&P500. Wells Fargo & Company MN now owns 115,326 shares of the biopharmaceutical company's stock worth $1,981,000 after buying an additional 6,604 shares in the last quarter. Coldstream Mgmt owns 6,898 shares or 0.04% of their United States portfolio. The stock decreased 0.38% or $0.36 during the last trading session, reaching $93.22. It has outperformed by 195.37% the S&P500. The stock of Nektar Therapeutics (NASDAQ:NKTR) has "Buy" rating given on Monday, April 9 by Cowen & Co. Therefore 100% are positive. Since October 18, 2017 according to StockzIntelligence Inc Nektar Therapeutics has 11 analyst reports. SunTrust maintained the stock with "Hold" rating in Thursday, November 9 report. Over the past twelve months, Nektar Therapeutics (NASDAQ:NKTR)'s stock was 68.29%. $67's average target is -33.33% below currents $100.5 stock price. The company's Market capitalization is $6.51B with the total Outstanding Shares of 332.99M. The rating was maintained by Roth Capital with "Buy" on Wednesday, August 30. The firm earned "Buy" rating on Wednesday, October 18 by Jefferies. Finally, HC Wainwright set a $125.00 target price on Nektar Therapeutics and gave the company a "buy" rating in a report on Monday, April 9th. They expect $-0.43 earnings per share, down 2.38 % or $0.01 from last year's $-0.42 per share.

Shares of Nektar Therapeutics (NASDAQ:NKTR) traded down 2.518% during mid-day trading on Tuesday, hitting $13.355. It also upped Hartford Finl Svcs Group Inc (NYSE:HIG) stake by 163,191 shares and now owns 1.76 million shares.

Since January 1, 0001, it had 0 buys, and 11 selling transactions for $40.88 million activity. KUEBLER CHRISTOPHER A sold $3.90M worth of Nektar Therapeutics (NASDAQ:NKTR) on Tuesday, March 6. 2,545 shares valued at $211,082 were sold by Thomsen Jillian B. on Friday, February 16. Swiss National Bank now owns 266,300 shares of the biopharmaceutical company's stock worth $15,903,000 after purchasing an additional 6,800 shares in the last quarter. $238,453 worth of stock was sold by Hora Maninder on Friday, February 16.

Sirva Inc (SIR) investors sentiment increased to 1.33 in 2017 Q4. That's change of 0.21, from 2017Q3's 1.4. It dropped, as 18 investors sold NKTR shares while 82 reduced holdings.

Several hedge funds and other institutional investors have recently made changes to their positions in NKTR. The investment professionals in our partner's database reported: 150.36 million shares, up from 148.76 million shares in 2017Q3. The New York-based Goldman Sachs Group has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Manufacturers Life Ins The holds 0.01% or 112,452 shares in its portfolio. State Of Alaska Department Of Revenue has 31,375 shares. The share price has yet to cross its 20 days moving average, floating at a distance of 0% and sits 6.01% higher versus its 50 days moving average. Paradigm Asset Limited Liability Corp has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Alliancebernstein Ltd Partnership invested in 263,506 shares. Following the transaction, the chief executive officer now owns 333,268 shares in the company, valued at approximately $25,268,379.76. Sabby Mngmt Ltd Liability Company holds 0.11% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 20,000 shares. 888.76 million shares or 103.84% more from 436.00 million shares in 2017Q3 were reported. Qs Limited Liability Corp accumulated 3,612 shares. Cambridge Invest Rech Advisors Inc stated it has 3,666 shares or 0% of all its holdings. (NYSE:GRUB) to report earnings on April, 26. SIR's profit will be $58.16 million for 7.20 P/E if the $0.65 EPS becomes a reality. The company's revenue was up 154.9% on a year-over-year basis. research analysts anticipate that Nektar Therapeutics will post -1.33 EPS for the current year. Piper Jaffray maintained Nektar Therapeutics (NASDAQ:NKTR) on Thursday, January 7 with "Overweight" rating. On Wednesday, January 10 the firm has "Buy" rating given by Canaccord Genuity. As per Thursday, November 9, the company rating was initiated by Canaccord Genuity. Susquehanna maintained the stock with "Hold" rating in Friday, February 9 report. KeyBanc Capital Markets maintained it with "Buy" rating and $7800 target in Sunday, July 16 report. The company was downgraded on Friday, July 29 by Monness Crespi. RBC Capital Markets initiated CenturyLink, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.